Bristol-Myers Squibb Co.

Links: Y! CELG MM R&D deep dive BMY Roulette CELG legacy IV board (still active) CELG legacy IV board (premium) BMY Roulette 2020

BMY / Message Board

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
3673	Re: Any thoughts on luspatercept revenue trajectory?	GN	Doolen		1	8/6/2020 9:54:35 AM

3672	Any thoughts on luspatercept revenue trajectory?	GN	Biotech2050		0	8/6/2020 9:43:23 AM

3671	Last question was about subcutaneous opdivo	GN	Biotech2050		3	8/6/2020 9:36:42 AM

3670	Did I understand correctly that the Trump executive order could effect "only" 9% of revenues?	GN	Biotech2050		1	8/6/2020 9:30:45 AM

3669	Initial Thoughts on 2Q20 Earnings BofA	GN	neednews		9	8/6/2020 8:49:26 AM

3668	Indeed it seems Keytruda increased sales came at the expense of Opdivo	GN	Biotech2050		0	8/6/2020 8:33:18 AM

3666	Re: Earnings	GN	Doolen		7	8/6/2020 7:16:04 AM

3665	Earnings	GN	cptspr		6	8/6/2020 7:07:35 AM

3664	Americas Healthcare: Pharmaceuticals: Favorable Eliquis patent decision should return focus to fundamentals ... GS	GN	neednews		6	8/6/2020 6:18:15 AM

3663	OncLive 5Aug2020 Article "FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma" (this is GSK's BCMA ADC with ORR 31%, bodes well for Ide-cel/bb21 ORR 82%, CR 39%, mPFS 12.1 months)	GN	JBWIN		6	8/5/2020 10:47:54 PM


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement